Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 21, 2004

View Archived Issues

Direct antiplatelet effects of the novel engineered human apyrase APT-102

Preclinical characterization of the orally active factor Xa inhibitor, DU-176b

Preclinical effects of the novel thrombopoietin receptor agonist, SB-559457, on hematopoietic cells

Acusphere enrolls 300 in pivotal program for AI-700

Alcon completes NDA filing for Retaane

Avanir commences NDA submission for Neurodex

Updates on Xyotax pivotal studies

No overall survival benefit with Iressa in ISEL study

Clevelox ESCAPE-1 study meets objectives

Positive data from ongoing studies of rhC1INH for hereditary angioedema

Exelixis plans phase I study of XL-880 for 2005

Abbott seeks U.S., European approvals of Humira for psoriatic arthritis

Allos Therapeutics acquires license to chemotherapeutic agent RH1

CXCR inhibition as a therapeutic strategy in leukemia

Potential neuroprotective effects for rifampicin in Parkinson's disease

Fast track designation for Remicade for ulcerative colitis

Scientists at Pfizer describe a novel series of PDE9 inhibitors

Abbott discloses MCH receptor antagonists in a recent patent

Compounds for the treatment of ischemic diseases described in patent literature

Sankyo patent claims chromane analogues and their use in diabetes, hyperlipidemia, etc.

A new series of beta3 receptor agonists in early development at Dainippon

Kyowa Hakko isolates antiinflammatory compound from a natural source

SB-715992 enters new phase II study for advanced ovarian cancer

INS-50589 Cardiovascular tested in new phase I study

Perifosine shows promise in the treatment of metastatic breast cancer

667-Coumate enters phase I development for breast cancer

Therapeutic benefits reported for modafinil in cocaine dependence and MDD

Cardiovascular risks halt use of celecoxib in study/News in Context

Lundbeck files for E.U. approval of Cipralex for generalized anxiety disorder

Avastin approved in Switzerland

New Invirase 500 mg receives FDA approval

Macugen approved for neovascular AMD

Myozyme MAA accepted in Europe for Pompe disease

TAK-559 placed on hold

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...